Drug Type Fusion protein |
Synonyms PEG sTNF-RI, Pegsunercept (USAN), Pegylated soluble tumour necrosis factor receptor type I + [2] |
Target |
Action inhibitors |
Mechanism TNF inhibitors(Tumor necrosis factor inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |

| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D05393 | Pegsunercept | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Rheumatoid Arthritis | Phase 2 | - | 01 May 2001 |
Not Applicable | 502 | Pegsunercept 400mg/kg weekly | wzvyriddlf(reccqgtjdk) = 9 resulted in withdrawal from the study jkwpcdikab (rltqwambrw ) View more | - | 12 Jun 2002 | ||
Pegsunercept 800mg/kg weekly | |||||||
Not Applicable | 195 | PEG sTNF-RI 400 μg/kg | guyfsfgalf(pfzwekryad) = xbfvjfvvst yyenvzpdcc (ixdfsmkfrt ) | Positive | 13 Jun 2001 | ||
PEG sTNF-RI 800 μg/kg | guyfsfgalf(pfzwekryad) = ookxfiyshk yyenvzpdcc (ixdfsmkfrt ) |






